Advances of neoadjuvant and conversion therapy with PD-1 inhibitors in gastric cancer
10.3760/cma.j.cn441530-20240728-00263
- VernacularTitle:程序性死亡受体1抑制剂在胃癌新辅助治疗及转化治疗中应用的研究进展
- Author:
Yufan TANG
1
;
Baiquan ZHOU
;
Simeng DAI
;
Bingbing WEN
;
Jixiang LIU
;
Luyao LI
;
Ruifang FAN
Author Information
1. 甘肃中医药大学第一临床医学院，兰州 730000
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms, advanced;
PD-1 inhibitor;
Neoadjuvant therapy;
Conversion therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2025;28(2):217-224
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer (GC) is one of the most common malignant tumors of the digestive system in China. With the progress of immunotherapy research, programmed death receptor-1 (PD-1) inhibitor-based combinatory therapy offers new ideas for the treatment of advanced gastric cancer. In recent years, with the increasing status of immunotherapy in the treatment of advanced gastric cancer, a growing number of domestic and international clinical studies shown that immunotherapy could achieve better efficacy in the neoadjuvant therapy and conversion therapy for patients with advanced gastric cancer. This paper reviews the current research progress on the application of PD-1 inhibitors in the neoadjuvant therapy and conversion therapy of gastric cancer.
